We are live on
!
Find out more
SGAM
Smith Group Asset Management Portfolio holdings
AUM
$2.46B
1-Year Est. Return
57.16%
This Fund
S&P 500
This Quarter
Est. Return
+12.25%
1 Year Est. Return
+57.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.91B
AUM Growth
+$100M
(+5.5%)
Cap. Flow
-$61.7M
Cap. Flow
% of AUM
-3.22%
Top 10 Holdings %
Top 10 Hldgs %
40.66%
Holding
350
New
52
Increased
58
Reduced
147
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lowe's Companies
LOW
|
+$21.7M |
| 2 |
Allstate
ALL
|
+$20.2M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$20.1M |
| 4 |
SGI
Somnigroup International
SGI
|
+$19.4M |
| 5 |
Generac Holdings
GNRC
|
+$16.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$30.3M |
| 2 |
Ciena
CIEN
|
+$25.4M |
| 3 |
Edwards Lifesciences
EW
|
+$22M |
| 4 |
Baxter International
BAX
|
+$20.9M |
| 5 |
Huntington Ingalls Industries
HII
|
+$19.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.47% |
| 2 | Consumer Discretionary | 15.93% |
| 3 | Healthcare | 15.71% |
| 4 | Communication Services | 8.84% |
| 5 | Financials | 8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
TG Therapeutics
TGTX
$7.52B
| $94K | ﹤0.01% |
+3,520
| New | +$81K |
|
|
CCXI
202
DELISTED
ChemoCentryx, Inc.
CCXI
| $90K | ﹤0.01% |
+1,650
| New | +$88.8K |
|
203
Louisiana-Pacific
LPX
$5.2B
| $79K | ﹤0.01% |
+2,690
| New | +$82.6K |
|
|
ALLK
204
DELISTED
Allakos
ALLK
| $78K | ﹤0.01% |
960
+310
| +48% | +$25.2K |
|
|
APLS
205
DELISTED
Apellis Pharmaceuticals
APLS
| $78K | ﹤0.01% |
+2,590
| New | +$77.4K |
|
206
Allogene Therapeutics
ALLO
$725M
| $74K | ﹤0.01% |
+1,970
| New | +$74.3K |
|
207
Xencor
XNCR
$1.6B
| $68K | ﹤0.01% |
1,760
| – | – |
|
208
Innospec
IOSP
$2.29B
| $65K | ﹤0.01% |
1,030
-9,308
| -90% | -$691K |
|
209
The RMR Group
RMR
$335M
| $65K | ﹤0.01% |
2,380
-6,620
| -74% | -$192K |
|
210
CareDx
CDNA
$2.44B
| $63K | ﹤0.01% |
1,650
| – | – |
|
211
Inovio Pharmaceuticals
INO
$76.1M
| $62K | ﹤0.01% |
+448
| New | +$93.4K |
|
212
Ironwood Pharmaceuticals
IRWD
$669M
| $61K | ﹤0.01% |
6,830
+2,690
| +65% | +$26.7K |
|
213
Heron Therapeutics
HRTX
$63.4M
| $55K | ﹤0.01% |
3,720
+910
| +32% | +$14.2K |
|
214
Bank of America
BAC
$447B
| $50K | ﹤0.01% |
2,095
+50
| +2% | +$1.25K |
|
215
Wells Fargo
WFC
$265B
| $43K | ﹤0.01% |
1,811
+250
| +16% | +$6.16K |
|
|
ICPT
216
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $43K | ﹤0.01% |
1,030
| – | – |
|
217
Blackrock
BLK
$175B
| $42K | ﹤0.01% |
74
+3
| +4% | +$1.71K |
|
218
BHP
BHP
$230B
| $41K | ﹤0.01% |
886
+348
| +65% | +$16.7K |
|
219
Citigroup
C
$227B
| $40K | ﹤0.01% |
930
+90
| +11% | +$4.48K |
|
220
US Bancorp
USB
$100B
| $38K | ﹤0.01% |
1,057
+70
| +7% | +$2.56K |
|
221
PNC Financial Services
PNC
$100B
| $34K | ﹤0.01% |
309
-13
| -4% | -$1.4K |
|
222
TotalEnergies
TTE
$195B
| $34K | ﹤0.01% |
986
-320
| -25% | -$12.2K |
|
223
Linde
LIN
$227B
| $31K | ﹤0.01% |
129
-40
| -24% | -$9.7K |
|
224
Regenxbio
RGNX
$688M
| $31K | ﹤0.01% |
1,140
| – | – |
|
|
BNY
225
Bank of New York Mellon
BNY
$108B
| $30K | ﹤0.01% |
862
+205
| +31% | +$7.46K |
|
Similar funds
M
GWM
QT
SCM
TW
KFA
SG
FFA
Smith Group Asset Management's Q3 2020 Portfolio in Review
As of Q3 2020, Smith Group Asset Management held 350 positions worth $1.91B, up 5.5% from $1.81B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Smith Group Asset Management withdrew a net $61.7M in Q3 2020, closing 44 positions and reducing 147 holdings. Its most notable exit was Oracle, an estimated $30.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 38% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Smith Group Asset Management opened a new position in Thermo Fisher Scientific worth $13.7M.
- Smith Group Asset Management's largest Q3 2020 buy was Thermo Fisher Scientific: 30,920 shares worth $13.7M.
- Smith Group Asset Management added most to Lowe's Companies in Q3 2020, an estimated $21.7M increase.
- Smith Group Asset Management's biggest Q3 2020 reduction was Bristol-Myers Squibb, cutting an estimated $14.5M.
- Smith Group Asset Management fully exited Oracle in Q3 2020, selling an estimated $30.3M.
- Smith Group Asset Management's ten largest holdings make up 41% of its $1.91B portfolio in Q3 2020.
- Smith Group Asset Management opened 52 new positions and closed 44 in Q3 2020.
- Smith Group Asset Management's portfolio value rose 5.5% quarter-over-quarter to $1.91B.
Based on Smith Group Asset Management's 13F filing for Q3 2020, filed 4 Nov 2020.